中国国际金融股份有限公司 关于上海仁度生物科技股份有限公司 预计 2026 年度日常关联交易的核查意见 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 公司第二届董事会独立董事专门会议第五次会议审议通过了《关于公司预计 2026 年度日常关联交易的议案》，独立董事认为：公司预计的 2026 年度日常关联交易符合 公司的经营发展需要，关联交易遵循了公平、合理的原则，该类关联交易对公司独立性 无重大不利影响，不会对公司及公司财务状况、经营成果产生重大不利影响，不存在损 害公司及全体股东特别是中小股东利益的情形。公司全体独立董事同意该事项，并同意 将该事项提交公司董事会审议。 公司于 2026 年 1 月 15 日召开第二届董事会第十五次会议审议通过了《关于公司预 计 2026 年度日常关联交易的议案》，表决结果为：赞成 7 票，无反对票，无弃权票。 （二）本次日常关联交易预计金额和类别 单位：万元 | 关联交易 | | 本次预计 | 占同类业 | 本年年初至 | 上年实际 | 占同类业 | 本 次 预 计 金 | | --- | --- | --- | --- | --- | --- | --- | ...

| 投资金额 | 不超过人民币 亿元（含本数） 4 | | --- | --- | | 投资种类 | 投资于安全性高、流动性较好的中低风险理财产品，包括但 | | | 不限于协定存款、七天通知存款、结构性存款大额存单、收 | | | 益凭证、债券投资、货币市场基金投资、委托理财等产品 | | 资金来源 | 自有资金 | 证券代码：688193 证券简称：仁度生物 公告编号：2026-002 上海仁度生物科技股份有限公司 关于公司使用闲置自有资金购买理财产品的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 基本情况 已履行的审议程序 公司于 2026 年 1 月 15 日召开第二届董事会第十五次会议，审议通过了《关 于公司使用闲置自有资金购买理财产品的议案》。上述事项在公司董事会审批权 限范围内，无需提交公司股东会审批。 特别风险提示 尽管公司拟投资的理财产品都经过严格的评估，但该类产品受货币政策等宏 观经济政策的影响较大，公司将根据经济形势以及金融市场的变化适时适量介入， 但不排除该项投资收益受到市场波动 ...

证券代码：688193 证券简称：仁度生物 公告编号：2026-003 公司于 2026 年 1 月 15 日召开第二届董事会第十五次会议审议通过了《关于 公司预计 2026 年度日常关联交易的议案》，表决结果为：赞成 7 票，无反对票， 无弃权票。 （二）本次日常关联交易预计金额和类别 上海仁度生物科技股份有限公司 关于公司预计 2026 年度日常关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 上海仁度生物科技股份有限公司（以下简称"公司"）第二届董事会独立董事 专门会议第五次会议审议通过了《关于公司预计 2026 年度日常关联交易的议案》， 独立董事认为：公司预计的 2026 年度日常关联交易符合公司的经营发展需要， 关联交易遵循了公平、合理的原则，该类关联交易对公司独立性无重大不利影响， 不会对公司及公司财务状况、经营成果产生重大不利影响，不存在损害公司及全 体股东特别是中小股东利益的情形。公司全体独立董事同意该事项，并同意将该 ...

中国国际金融股份有限公司 关于上海仁度生物科技股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为上 海仁度生物科技股份有限公司（以下简称"仁度生物"或"公司"）首次公开发行 股票并上市持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》《上海 证券交易所科创板股票上市规则》《上市公司募集资金监管规则》和《上海证券交 易所科创板上市公司自律监管指引第 1 号——规范运作》等有关规定，对仁度生物 拟使用部分暂时闲置募集资金进行现金管理事项进行了审慎的核查，具体核查情况 如下： 一、投资情况概述 （一）投资目的 为提高公司募集资金使用效率，在不影响募集资金投资项目建设正常进行的情 况下，根据募集资金投资项目的投资计划和建设进度，合理利用部分暂时闲置募集 资金进行现金管理，增加公司资金收益，为公司及股东获取更多回报。 （二）投资金额 公司拟使用最高余额不超过人民币 3.9 亿元（含本数）的暂时闲置募集资金进 行现金管理，使用期限自公司董事会审议通过之日起 12 个月有效。上述额度在决 议有效期内，资金可以滚动使用，并于到期后归还至募集资 ...

证券代码：688193 证券简称：仁度生物 公告编号：2026-004 上海仁度生物科技股份有限公司 关于公司募投项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海仁度生物科技股份有限公司（简称"公司"）于 2026 年 1 月 15 日召开第 二届董事会第十五次会议，审议通过了《关于公司募投项目延期的议案》，同意 公司对首次公开发行股票募集资金投资项目（以下简称"募投项目"）"精准诊断试 剂和智能设备产业化研发项目"、"营销网络建设项目"达到预定可使用状态的时 间进行延期。具体情况公告如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 经中国证券监督管理委员会作出《关于同意上海仁度生物科技股份有限公司 首次公开发行股票注册的批复》（证监许可[2022]332号文），并经上海证券交易 所同意，公司于2022年3月向社会公开发行人民币普通股10,000,000股，每股面值 人民币1.00元，溢价发行，每股发行价为人民币72.65元，募集资金总额为人民币 726,500,000.00元，扣除不 ...

上海仁度生物科技股份有限公司 关于公司使用部分暂时闲置募集资金进行现金管理 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资种类：安全性高、流动性好、具有合法经营资格且为本金保障型 的金融机构销售的投资产品（包括协定存款、定期存款、通知存款、大额存 单、结构性存款、收益凭证等）。 证券代码：688193 证券简称：仁度生物 公告编号：2026-005 投资金额：最高不超过人民币 3.9 亿元（含本数）。 已履行的审议程序 上海仁度生物科技股份有限公司（以下简称"公司"）于 2026 年 1 月 15 日召 开第二届董事会第十五次会议，审议通过了《关于公司使用部分暂时闲置募集资 金进行现金管理的议案》，保荐机构中国国际金融股份有限公司（以下简称"保 荐机构"）对上述事项出具了明确的核查意见。上述事项在公司董事会审批权限 范围内，无需提交公司股东会审议。 特别风险提示 尽管公司拟投资安全性高、流动性好且为本金保障型的投资产品，总体风险 可控，但该类产品受货币政策等宏观经济政策的影响较大，公司将根据经济形 ...

本议案无需提交股东会审议。 证券代码：688193 证券简称：仁度生物 公告编号：2026-001 上海仁度生物科技股份有限公司 第二届董事会第十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海仁度生物科技股份有限公司（以下简称"公司"）第二届董事会第十五次 会议于 2026 年 1 月 15 日以现场结合通讯的表决方式在公司会议室召开，会议应 到董事 7 人，实到董事 7 人，出席董事占应出席人数的 100%。公司高级管理人 员列席了董事会会议。本次董事会会议的召集、召开程序符合公司章程和有关法 律、法规的要求。经与会董事审议和表决，会议形成决议如下： 一、审议通过《关于公司使用闲置自有资金购买理财产品的 议案》 表决结果：同意 7 票，反对 0 票，弃权 0 票。 具体内容详见本公司 2026 年 1 月 17 日于上海证券交易所网站 （www.sse.com.cn）披露的《关于公司使用闲置自有资金购买理财产品的公告》 （公告编号：2026-002）。 二、审议通过《关于公司预计 2026 年度日常关 ...

Group 1 - Haitai Xinguang, based in Qingdao, specializes in the research, production, and sales of medical endoscope instruments and optical products, being a leading enterprise in the domestic medical endoscope optical field [1][30] - The company has established long-term collaborations with international medical giants such as Karl Storz and Olympus, and its high-definition optical imaging technology supports navigation equipment for neurosurgery [1][30] - By 2026, the market demand for its high-end optical components is expected to further release due to the recovery of the medical device sector and the advancement of brain-computer interface medical applications [1][30] Group 2 - Huqiang Technology, registered in Yichang, focuses on special protective equipment, pharmaceutical packaging, and medical devices, with a strong advantage in public health emergency material supply [2][31] - Its medical protective equipment is applicable in sterile operating environments for brain-computer interface implantation surgeries, enhancing product competitiveness in the medical device sector [2][31] Group 3 - Zhengde Medical, headquartered in Shaoxing, is a leading enterprise in the medical dressing industry, with a product matrix covering medical dressings, infection control, and rehabilitation care [3][32] - The company's surgical infection control products meet the sterile operation requirements for brain-computer interface implantation surgeries, and its rehabilitation products cater to post-operative patient management needs [3][32] - By 2026, the surgical infection control consumables business is expected to see market growth as brain-computer interface medical applications accelerate [3][32] Group 4 - Linuo Pharmaceutical Packaging, based in Jinan, specializes in the research, production, and sales of pharmaceutical packaging materials, including sterile medical device packaging suitable for brain-computer interface components [4][33] - The company is gradually expanding into the high-end medical device packaging market, seizing opportunities in the brain-computer interface industry [4][33] Group 5 - Rendu Biotech, located in Shanghai, focuses on RNA molecular diagnostic technology, with applications in infection detection post-brain-computer interface implantation surgeries [5][34] - The company’s post-operative infection detection reagents are expected to see new demand growth by 2026 as brain-computer interface clinical surgeries are promoted [5][34] Group 6 - Huangshan Capsule, based in Anhui, specializes in the research and production of pharmaceutical hollow capsules, gradually expanding into medical device auxiliary materials [6][36] - The company’s medical capsule carriers can adapt to the encapsulation needs of sustained-release bioelectrodes in brain-computer interface devices [6][36] Group 7 - ST Kelly, headquartered in Suzhou, focuses on medical device research and production, particularly in ultrasound equipment and rehabilitation devices [7][37] - The company’s ultrasound diagnostic equipment can be used for pre-operative brain tissue imaging assessments in brain-computer interface surgeries [7][37] Group 8 - Aotai Biotech, based in Hangzhou, specializes in rapid diagnostic reagents, with its rapid infection detection reagents applicable in brain-computer interface clinical settings [8][38] - The company is developing rapid detection products for post-operative neurological function assessment related to brain-computer interfaces [8][38] Group 9 - Dongfang Ocean, located in Yantai, focuses on marine biological medical materials, with collagen materials applicable as coatings for brain-computer interface electrodes [9][39] - The company is increasing its R&D investment in the medical device sector, particularly in the integration of biological medical materials with brain-computer interface devices by 2026 [9][39] Group 10 - Shuoshi Biotech, based in Taizhou, specializes in nucleic acid detection technology, with products applicable for precise diagnosis of post-operative brain infections in brain-computer interface surgeries [10][40] - The company is exploring detection technologies related to neurotransmitters in brain-computer interfaces, aiming for breakthroughs in neurological disease diagnostics [10][40] Group 11 - Guofa Co., located in Beihai, focuses on pharmaceutical manufacturing and medical device sales, with a distribution network covering Guangxi and surrounding areas [11][41] - The company plans to increase its agency layout for high-end medical devices related to brain-computer interfaces by 2026 [11][41] Group 12 - Nanwei Co., based in Nantong, specializes in medical dressings and hygiene products, with its adhesive dressings suitable for post-operative care in brain-computer interface surgeries [12][42] - The company is enhancing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [12][42] Group 13 - Mingde Biotech, located in Wuhan, is a leading enterprise in the field of rapid diagnostic reagents, with products applicable for monitoring vital signs during brain-computer interface surgeries [13][43] - The company is developing rapid assessment devices for post-operative neurological function related to brain-computer interfaces [13][43] Group 14 - Hualan Co., based in Wuxi, specializes in medical rubber products, with its rubber sealing components applicable in fluid control systems for brain-computer interface devices [14][44] - The company is collaborating with research institutions to develop rubber insulation components for brain-computer interface electrodes [14][44] Group 15 - Yuyue Medical, headquartered in Danyang, is a leading enterprise in home medical devices, with products applicable in brain-computer interface surgeries [15][45] - The company is increasing its R&D on medical-grade rehabilitation robots, aiming to integrate brain-computer interface technology with rehabilitation devices [15][45] Group 16 - Shengxiang Biotech, located in Changsha, focuses on nucleic acid detection technology, with products applicable for rapid diagnosis of central nervous system infections post-brain-computer interface surgeries [16][46] - The company is exploring gene detection technologies related to neurological genetic diseases, expanding the application boundaries of molecular diagnostics [16][46] Group 17 - Jiga Development, based in Jinan, focuses on high-end medical device incubation and industrialization, particularly in brain-computer interface-related medical device enterprises [17][47] - The company is responsible for industrial park construction and resource integration for brain-computer interface medical device companies [17][47] Group 18 - Anxu Biotech, located in Hangzhou, specializes in rapid diagnostic reagents, with products applicable for instant infection screening during brain-computer interface surgeries [18][48] - The company is developing rapid detection products for neurotransmitters related to brain-computer interfaces, aiming for breakthroughs in neurological function assessment [18][48] Group 19 - Wantai Biotech, based in Beijing, is a comprehensive enterprise in biopharmaceuticals and medical devices, with products applicable for biochemical index detection post-brain-computer interface surgeries [19][49] - The company is exploring biopharmaceutical development related to brain-computer interfaces, seeking new growth points in nerve repair [19][49] Group 20 - Jiuan Medical, located in Tianjin, focuses on home health devices, with products applicable for synchronized monitoring of brain signals and vital signs in brain-computer interface scenarios [20][50] - The company is increasing its R&D investment in brain-computer interface wearable devices, aiming to create an intelligent medical ecosystem [20][50] Group 21 - Jidan Biotech, based in Nanjing, specializes in POCT reagents and instruments, with products applicable for cardiovascular function assessment in brain-computer interface surgeries [21][51] - The company is developing rapid detection products for post-operative cerebrovascular diseases related to brain-computer interfaces [21][51] Group 22 - Wanfeng Biotech, located in Guangzhou, is a leading enterprise in the POCT field, with products applicable for instant infection screening during brain-computer interface surgeries [22][52] - The company is developing neurobiomarker detection reagents to assess post-operative neurological function recovery, providing comprehensive support for brain-computer interface surgeries [22][52] Group 23 - Haier Biotech, based in Qingdao, specializes in low-temperature storage devices for biological materials, with applications in brain-computer interface-related biological sample preservation [23][53] - The company is increasing its R&D on high-end medical storage devices tailored for brain-computer interface biological materials by 2026 [23][53] Group 24 - Haooubo, located in Suzhou, focuses on immune diagnostic reagents and instruments, with products applicable for immune function assessment in brain-computer interface surgeries [24][54] - The company is developing detection reagents for immune rejection post-brain-computer interface implantation, providing technical support for surgical complications [24][54] Group 25 - Shandong Pharmaceutical Glass, based in Zibo, is a leading enterprise in pharmaceutical glass, with products applicable for insulation packaging of brain-computer interface electrodes [25][55] - The company is expanding into the high-end medical device glass materials market, targeting the brain-computer interface industry [25][55] Group 26 - Innotech, located in Langfang, specializes in infectious disease diagnostic reagents, with products applicable for pre-operative lung infection screening in brain-computer interface surgeries [26][56] - The company is developing rapid detection products for post-operative lung infections related to brain-computer interfaces, aiming for breakthroughs in post-operative complication detection [26][56] Group 27 - Jianer Kang, based in Changzhou, focuses on medical dressings and rehabilitation care products, with its antibacterial medical dressings applicable for post-operative care in brain-computer interface surgeries [27][59] - The company is increasing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [27][59]

Group 1 - The medical device sector increased by 0.56% on December 19, with Kangzhong Medical leading the gains [1] - The Shanghai Composite Index closed at 3890.45, up 0.36%, while the Shenzhen Component Index closed at 13140.22, up 0.66% [1] - Notable gainers in the medical device sector included Kangzhong Medical, which rose by 7.36% to a closing price of 44.90, and Rendu Biotech, which increased by 6.78% to 50.40 [1] Group 2 - The medical device sector experienced a net inflow of 3.65 million yuan from institutional investors, while retail investors saw a net inflow of 15 million yuan [2] - Major stocks with significant net inflows included Rejing Bio with 49.71 million yuan and Yuyue Medical with 43.84 million yuan [3] - Conversely, retail investors showed net outflows in several stocks, including Yuyue Medical and Mairui Medical, indicating a mixed sentiment in the market [3]

Group 1 - The Shanghai Composite Index closed at 3887.81 points, above the six-month moving average, with a gain of 0.30% [1] - The total trading volume of A-shares reached 1,390.087 billion yuan [1] - A total of 249 A-shares have surpassed the six-month moving average, with notable stocks including GQY Vision, Hongwei Technology, and Zhongwang Fabric, showing significant deviation rates of 12.05%, 9.88%, and 8.75% respectively [1] Group 2 - GQY Vision (300076) had a daily increase of 13.08% with a turnover rate of 10.52%, and its latest price was 7.35 yuan, showing a deviation rate of 12.05% [1] - Hongwei Technology (688711) increased by 12.34% with a turnover rate of 15.68%, latest price at 27.50 yuan, and a deviation rate of 9.88% [1] - Zhongwang Fabric (605003) rose by 9.98% with a turnover rate of 1.76%, latest price at 25.78 yuan, and a deviation rate of 8.75% [1]